Search clinical trial records

# Search clinical trial records

Find clinical study protocols and outcomes.
Usage limits: Restricted clinical-trial source, short responses, 1-10 results. Billed from total_deduction_dollars; trial records are not efficacy or safety certification.
Draft retail price: at cost from the upstream USD meter; no markup. Only the documented data sources are allowed.
Request contract: include all six declared body fields. Send search_type=proprietary, response_length=short, and the exact max_price and included_sources shown in the example; these are constrained source settings.
Documentation: https://openany.si/apis/a21c72ef-409f-42f1-9b51-a1737ac60eb6
Method: POST
Endpoint: https://api.openany.si/v1/agent-apis/treg/call/valyu.health.trials.search
Price: $1 / 1 upstream_usd
Provider: treg
Contract revision: 2
Price source: selected implementation in the OpenAny public API catalog. Price update time: not supplied.

Use OPENANY_API_KEY from the environment. API Key calls use your shared balance.

## Prepared request
```bash
curl \
  'https://api.openany.si/v1/agent-apis/treg/call/valyu.health.trials.search' \
  -X POST \
  -H "Authorization: Bearer $OPENANY_API_KEY" \
  -H 'Content-Type: application/json' \
  --data-raw '{
  "included_sources": [
    "valyu/valyu-clinical-trials"
  ],
  "max_num_results": 1,
  "max_price": 5,
  "query": "semaglutide type 2 diabetes clinical trial",
  "response_length": "short",
  "search_type": "proprietary"
}'
```

## API contract
```json
{
  "resource_type": "api",
  "name": "Search clinical trial records",
  "endpoint": "https://api.openany.si/v1/agent-apis/treg/call/valyu.health.trials.search",
  "method": "POST",
  "content_type": "application/json",
  "execution_mode": "sync",
  "authentication": {
    "type": "bearer",
    "environment_variable": "OPENANY_API_KEY"
  },
  "inputs": [
    {
      "description": "Find clinical study protocols and outcomes.\nUsage limits: Restricted clinical-trial source, short responses, 1-10 results. Billed from total_deduction_dollars; trial records are not efficacy or safety certification.\nDraft retail price: at cost from the upstream USD meter; no markup. Only the documented data sources are allowed.\nRequest contract: include all six declared body fields. Send search_type=proprietary, response_length=short, and the exact max_price and included_sources shown in the example; these are constrained source settings.",
      "json_schema": {
        "additionalProperties": false,
        "properties": {
          "included_sources": {
            "description": "Required TREG source constraint; send this exact value.",
            "enum": [
              [
                "valyu/valyu-clinical-trials"
              ]
            ],
            "example": [
              "valyu/valyu-clinical-trials"
            ],
            "items": {
              "type": "string"
            },
            "maxItems": 1,
            "minItems": 1,
            "type": "array"
          },
          "max_num_results": {
            "description": "",
            "example": 1,
            "maximum": 10,
            "minimum": 1,
            "type": "integer"
          },
          "max_price": {
            "description": "Required TREG source constraint; send this exact value.",
            "enum": [
              5
            ],
            "example": 5,
            "type": "number"
          },
          "query": {
            "description": "",
            "example": "Clinical trials for semaglutide in type 2 diabetes",
            "type": "string"
          },
          "response_length": {
            "description": "Required TREG source constraint; send this exact value.",
            "enum": [
              "short"
            ],
            "example": "short",
            "type": "string"
          },
          "search_type": {
            "description": "Required TREG source constraint; send this exact value.",
            "enum": [
              "proprietary"
            ],
            "example": "proprietary",
            "type": "string"
          }
        },
        "required": [
          "query",
          "max_num_results",
          "search_type",
          "max_price",
          "response_length",
          "included_sources"
        ],
        "type": "object"
      },
      "location": "body",
      "name": "body",
      "nullable": false,
      "pointer": "",
      "required": true,
      "type": "object"
    }
  ],
  "billing": {
    "currency": "USD",
    "mode": "usage",
    "priceMicroUsd": "1000000",
    "rounding": "ceil",
    "unit": "upstream_usd",
    "unitQuantity": "1"
  },
  "examples": [
    {
      "http_status": 200,
      "name": "Third-party reference · Testnet 2026-11-04: success",
      "request": {
        "body": {
          "included_sources": [
            "valyu/valyu-clinical-trials"
          ],
          "max_num_results": 1,
          "max_price": 5,
          "query": "semaglutide type 2 diabetes clinical trial",
          "response_length": "short",
          "search_type": "proprietary"
        },
        "headers": {},
        "path": {},
        "query": {}
      },
      "response_body": {
        "error": "",
        "query": "semaglutide type 2 diabetes clinical trial",
        "results": [
          {
            "content": "{\n  \"nct_id\": \"NCT07563699\",\n  \"brief_title\": \"Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus\",\n  \"official_title\": \"A Prospective, Multicenter, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus\",\n  \"acronym\": \"N/A\",\n  \"overall_status\": \"RECRUITING\",\n  \"why_stopped\": \"N/A\",\n  \"start_date\": \"2026-08-09\",\n  \"start_date_type\": \"ACTUAL\",\n  \"completion_date\": \"2028-05\",\n  \"completion_date_type\": \"ESTIMATED\",\n  \"study_completion_date\": \"2028-06\",\n  \"study_completion_date_type\": \"ESTIMATED\",\n  \"study_first_posted\": \"2026-05-04\",\n  \"last_update_posted\": \"2026-08-20\",\n  \"results_first_posted\": \"N/A\",\n  \"study_type\": \"INTERVENTIONAL\",\n  \"phases\": \"PHASE1, PHASE2\",\n  \"allocation\": \"NON_RANDOMIZED\",\n  \"intervention_model\": \"SEQUENTIAL\",\n  \"masking\": \"NONE\",\n  \"primary_purpose\": \"TREATMENT\",\n  \"enrollment_count\": 24,\n  \"enrollment_type\": \"ESTIMATED\",\n  \"brief_summary\": \"Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an approved and well-established therapy for type 2 diabetes mellitus (T2DM), providing both robust glycemic control and weight reduction. Semaglutide Depot, is a long-acting formulation of semaglutide, designed for once every four weeks administration, intended to reduce treatment burden, and improve adherence supporting sustained glycemic control over time.\\n\\nThis Phase I/Ila dose escalation study design to evaluate the safety, tolerability, pharmacokinetics and efficacy of Semaglutide Depot in adults with T2DM.\",\n  \"detailed_description\": \"Study Title:\\n\\nA Prospective, Multicenter, Open-Label, Dose Escalation Phase I/Ila Study to Assess the Safety, Tolerability, and Efficacy of Semaglutide Depot in Subjects with Type 2 Diabetes Mellitus\\n\\nBackground:\\n\\nType 2 diabetes mellitus (T2DM) is a chronic condition in which the body cannot properly use insulin, leading to elevated blood glucose levels. It is often associated with overweight or obesity and can lead to serious complications if not well controlled.\\n\\nSemaglutide, is a GLP 1 receptor agonist, that helps lower blood glucose by increasing insulin secretion, reducing glucagon (a hormone that raises blood glucose), slowing gastric emptying, and reducing appetite. In addition to improving glycemic control, it also supports weight loss and has demonstrated cardiovascular benefits. Semaglutide is already approved in several formulations (examples: Ozempic® for type 2 diabetes and Wegovy® for weight management), but these require once-weekly injections.\\n\\nSemaglutide Depot (SG Depot) is a new, long-acting formulation developed by Mapi Pharma Ltd. It is designed to be injected once every 4 weeks (once monthly), which may make treatment easier and improve adherence for people with diabetes.\\n\\nStudy Design:\\n\\n* Type: Phase I/Ila, open label, dose escalation study, prospective study\\n* Sponsor: Mapi Pharma Ltd., Ness Ziona, Israel\\n* Sites: Tel Aviv, Israel\\n* Participants: Up to 24 adults with type 2 diabetes\\n* Groups: Participants will be divided into 4 sequential dose cohorts: 2 mg, 4 mg, 6 mg and 8 mg\\n* Dose escalation: will be allowed only after review of safety data\",\n  \"conditions\": \"Diabete Type 2\",\n  \"keywords\": \"Diabetes, Semaglutide Depot, Long-acting semaglutide, SG Depot, semaglutide LAI\",\n  \"eligibility_criteria\": \"Inclusion Criteria:\\n\\n1. Adults aged 18-64 years with T2DM, BMI 25-35 kg/m2\\n2. On stable Semaglutide 1 mg weekly and for at least 3 months\\n3. HbA1c \\\\<8%, eGFR≥60 ml/minute\\n4. For women: either non-childbearing potential or agreement to use acceptable contraception\\n\\nExclusion Criteria:\\n\\n1. Participation in another investigational drug clinical study within 3 months\\n2. History of cardiovascular or cerebrovascular disease\\n3. Neuropathy or retinopathy or macular edema necessitating medical treatment\\n4. Type 1 diabetes\\n5. Unstable weight (\\\\> 5% change in the last 3 months)\\n6. Current use of insulin and /or sulfonylureas and/or glinides\\n7. Known contraindications to Semaglutide (per FDA-approved Semaglutide label)\\n8. Recent immunosuppressive therapy (within 90 days) or chemotherapy for malignancy within 5 years\\n9. Moderate or severe hepatic impairment, (ALT or AST\\\\> 2 x upper limit of normal (ULN)\\n10. Severe hypertriglyceridemia (triglycerides \\\\>500 mg/dl)\\n11. Pregnant or breast feeding\\n12. Any condition that may increase risk or interfere with study participation (per Investigator judgement)\",\n  \"gender\": \"ALL\",\n  \"min_age\": \"18 Years\",\n  \"max_age\": \"64 Years\",\n  \"healthy_volunteers\": false,\n  \"interventions\": [\n    {\n      \"type\": \"DRUG\",\n      \"name\": \"SG Depot 2 mg\",\n      \"description\": \"2 mg administered subcutaneously (s.c., under the skin) once every 4 weeks\",\n      \"arm_group_labels\": \"\"\n    },\n    {\n      \"type\": \"DRUG\",\n      \"name\": \"SG Depot 4 mg\",\n      \"description\": \"4 mg administered subcutaneously (s.c., under the skin) once every 4 weeks\",\n      \"arm_group_labels\": \"\"\n    },\n    {\n      \"type\": \"DRUG\",\n      \"name\": \"SG Depot 6 mg\",\n      \"description\": \"6 mg administered subcutaneously (s.c., under the skin) once every 4 weeks\",\n      \"arm_group_labels\": \"\"\n    },\n    {\n      \"type\": \"DRUG\",\n      \"name\": \"SG Depot 8 mg\",\n      \"description\": \"8 mg administered subcutaneously (s.c., under the skin) once every 4 weeks\",\n      \"arm_group_labels\": \"\"\n    }\n  ],\n  \"primary_outcomes\": [\n    {\n      \"measure\": \"The rate of treatment-associated adverse events (AEs)\",\n      \"time_frame\": \"Through study completion, up to 28 weeks for each subject\",\n      \"description\": \"N/A\"\n    },\n    {\n      \"measure\": \"Plasma concentration of semaglutide\",\n      \"time_frame\": \"Through study completion, up to 28 weeks for each subject\",\n      \"description\": \"N/A\"\n    }\n  ],\n  \"secondary_outcomes\": [\n    {\n      \"measure\": \"Change in HbA1c\",\n      \"time_frame\": \"Baseline (week 0), week 12\",\n      \"description\": \"N/A\"\n    },\n    {\n      \"measure\": \"Change in fasting plasma glucose from baseline\",\n      \"time_frame\": \"Baseline (week 0), week 12\",\n      \"description\": \"N/A\"\n    },\n    {\n      \"measure\": \"Change in body weight from baseline\",\n      \"time_frame\": \"Baseline (week 0), week 12\",\n      \"description\": \"N/A\"\n    },\n    {\n      \"measure\": \"The maximal tolerated dose (MTD) of SG Depot\",\n      \"time_frame\": \"Through study completion, up to 28 weeks for each subject\",\n      \"description\": \"N/A\"\n    }\n  ],\n  \"other_outcomes\": [],\n  \"lead_sponsor\": \"Mapi Pharma Ltd.\",\n  \"lead_sponsor_class\": \"INDUSTRY\",\n  \"collaborators\": [],\n  \"has_dmc\": \"N/A\",\n  \"is_fda_regulated_drug\": false,\n  \"is_fda_regulated_device\": false,\n  \"locations\": [\n    {\n      \"facility\": \"Mapi pharma Investigational Site ISR001\",\n      \"city\": \"Tel Aviv\",\n      \"state\": \"N/A\",\n      \"country\": \"Israel\",\n      \"zip\": \"6423906\",\n      \"status\": \"RECRUITING\",\n      \"contacts\": []\n    }\n  ],\n  \"central_contacts\": [\n    {\n      \"name\": \"Roy Eldor, Professor\",\n      \"role\": \"CONTACT\",\n      \"phone\": \"972-36974243\",\n      \"email\": \"[email protected]\"\n    }\n  ],\n  \"overall_officials\": [],\n  \"references\": [],\n  \"ipd_sharing\": \"NO\",\n  \"ipd_description\": \"N/A\",\n  \"has_results\": false,\n  \"participant_flow\": {},\n  \"baseline_characteristics\": [],\n  \"outcome_results\": [],\n  \"adverse_events\": [],\n  \"study_limitations\": \"N/A\",\n  \"point_of_contact\": {}\n}",
            "data_type": "structured",
            "id": "NCT07563699",
            "length": 7408,
            "metadata": {},
            "price": 0.005,
            "publication_date": "2026-05-04",
            "relevance_score": 0.97,
            "source": "valyu/valyu-clinical-trials",
            "title": "A Prospective, Multicenter, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus",
            "url": "https://clinicaltrials.gov/study/NCT07563699"
          }
        ],
        "results_by_source": {
          "proprietary": 1,
          "web": 0
        },
        "success": true,
        "total_characters": 7408,
        "total_deduction_dollars": 0.005,
        "tx_id": "tx_ccf434de-9ac8-4046-88d9-bd4f747eaa2b"
      }
    }
  ]
}
```